TA-01 is a potent CK1 and p38 MAPK inhibitor, with IC50s of 6.4 nM, 6.8 nM, 6.7 nM for CK1ε, CK1δ and p38 MAPK, respectively.

p38 MAP kinase:6.7 nM, CKIδ:6.8 nM, CKIϵ:6.4 nM 

TA-01是一种强效的CK1和p38 MAPK抑制剂，其IC50分别为CK1ε（6.4 nM）、CK1δ（6.8 nM）和p38 MAPK（6.7 nM）。TA-01（5 μM）不具有细胞毒性，能完全抑制心脏发生，但在较低浓度时可以诱导心脏发生[1]。

Compounds (TA-01) are dissolved in DMSO?and tested at?10 μM concentrations?against a panel of 97 kinases, which are related to stem cell differentiation and cell signaling pathways. Kinome profiling is carried out by kinase profiling service[1].

HES-3, H7 and IPS are harvested and seeded at 1.1 × 106 cells/mL as EBs in ultra-low attachment 12-well plates in bSFS medium: DMEM supplemented with 2 mM l-glutamine, 0.182 mM sodium pyruvate, 1% non-essential amino acids, 0.1 mM β-mercaptoethanol, 5.6 mg/L transferrin, 20 μg/L sodium selenite, 0.25% (w/vol) Bovine Serum Albumin and 0.25% (w/vol) Hysoy. Cells are incubated at 37°C and 5% CO2 to allow EB formation. The medium is refreshed after 1 day and then every 2-3 days. Cells are stimulated with the respective compounds (TA-01) dissolved in DMSO (1 μL DMSO/mL of media) starting from day 1 or day 4, until day 8. CHIR99021 is applied for the first 24 h only[1].